Tags

Type your tag names separated by a space and hit enter

The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures.
Osteoporos Int. 2012 Aug; 23(8):2141-50.OI

Abstract

The effect of teriparatide and risedronate on back pain was tested, and there was no difference in the proportion of patients experiencing a reduction in back pain between groups after 6 or 18 months. Patients receiving teriparatide had greater increases in bone mineral density and had fewer vertebral fractures.

INTRODUCTION

This study aimed to understand the effect of teriparatide in reducing back pain in patients with prevalent back pain and vertebral fracture compared to risedronate.

METHODS

In an 18-month randomized, double-blind, double-dummy trial, we investigated the effects of teriparatide (20 μg/day) vs. risedronate (35 mg/week) in postmenopausal women with back pain likely due to vertebral fracture. The primary objective was to compare the proportion of subjects reporting ≥30% reduction in worst back pain severity from baseline to 6 months as assessed by a numeric rating scale in each treatment group. Pre-specified secondary and exploratory outcomes included assessments of average and worst back pain at additional time points, disability and quality of life, bone mineral density, incidence of fractures, and safety.

RESULTS

At 6 months, 59% of teriparatide and 57% of risedronate patients reported ≥30% reduction in worst back pain and there were no differences between groups in the proportion of patients experiencing reduction in worst or average back pain at any time point, disability, or quality of life. There was a greater increase from baseline in bone mineral density at the lumbar spine (p = 0.001) and femoral neck (p = 0.02) with teriparatide compared to risedronate and a lower incidence of vertebral fractures at 18 months (4% teriparatide and 9% risedronate; p = 0.01). Vertebral fractures were less severe (p = 0.04) in the teriparatide group. There was no difference in the overall incidence of adverse events.

CONCLUSIONS

Although there were no differences in back pain-related endpoints, patients receiving teriparatide had greater skeletal benefit than those receiving risedronate.

Authors+Show Affiliations

Department of Endocrinology, Osteoporosis, and Reproductive Medicine, Philipps-University of Marburg, Marburg, Germany. hadji@med.uni-marburg.deNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22159672

Citation

Hadji, P, et al. "The Effect of Teriparatide Compared With Risedronate On Reduction of Back Pain in Postmenopausal Women With Osteoporotic Vertebral Fractures." Osteoporosis International : a Journal Established as Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, vol. 23, no. 8, 2012, pp. 2141-50.
Hadji P, Zanchetta JR, Russo L, et al. The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures. Osteoporos Int. 2012;23(8):2141-50.
Hadji, P., Zanchetta, J. R., Russo, L., Recknor, C. P., Saag, K. G., McKiernan, F. E., Silverman, S. L., Alam, J., Burge, R. T., Krege, J. H., Lakshmanan, M. C., Masica, D. N., Mitlak, B. H., & Stock, J. L. (2012). The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures. Osteoporosis International : a Journal Established as Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 23(8), 2141-50. https://doi.org/10.1007/s00198-011-1856-y
Hadji P, et al. The Effect of Teriparatide Compared With Risedronate On Reduction of Back Pain in Postmenopausal Women With Osteoporotic Vertebral Fractures. Osteoporos Int. 2012;23(8):2141-50. PubMed PMID: 22159672.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures. AU - Hadji,P, AU - Zanchetta,J R, AU - Russo,L, AU - Recknor,C P, AU - Saag,K G, AU - McKiernan,F E, AU - Silverman,S L, AU - Alam,J, AU - Burge,R T, AU - Krege,J H, AU - Lakshmanan,M C, AU - Masica,D N, AU - Mitlak,B H, AU - Stock,J L, Y1 - 2011/12/13/ PY - 2011/08/01/received PY - 2011/11/04/accepted PY - 2011/12/14/entrez PY - 2011/12/14/pubmed PY - 2012/12/18/medline SP - 2141 EP - 50 JF - Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA JO - Osteoporos Int VL - 23 IS - 8 N2 - UNLABELLED: The effect of teriparatide and risedronate on back pain was tested, and there was no difference in the proportion of patients experiencing a reduction in back pain between groups after 6 or 18 months. Patients receiving teriparatide had greater increases in bone mineral density and had fewer vertebral fractures. INTRODUCTION: This study aimed to understand the effect of teriparatide in reducing back pain in patients with prevalent back pain and vertebral fracture compared to risedronate. METHODS: In an 18-month randomized, double-blind, double-dummy trial, we investigated the effects of teriparatide (20 μg/day) vs. risedronate (35 mg/week) in postmenopausal women with back pain likely due to vertebral fracture. The primary objective was to compare the proportion of subjects reporting ≥30% reduction in worst back pain severity from baseline to 6 months as assessed by a numeric rating scale in each treatment group. Pre-specified secondary and exploratory outcomes included assessments of average and worst back pain at additional time points, disability and quality of life, bone mineral density, incidence of fractures, and safety. RESULTS: At 6 months, 59% of teriparatide and 57% of risedronate patients reported ≥30% reduction in worst back pain and there were no differences between groups in the proportion of patients experiencing reduction in worst or average back pain at any time point, disability, or quality of life. There was a greater increase from baseline in bone mineral density at the lumbar spine (p = 0.001) and femoral neck (p = 0.02) with teriparatide compared to risedronate and a lower incidence of vertebral fractures at 18 months (4% teriparatide and 9% risedronate; p = 0.01). Vertebral fractures were less severe (p = 0.04) in the teriparatide group. There was no difference in the overall incidence of adverse events. CONCLUSIONS: Although there were no differences in back pain-related endpoints, patients receiving teriparatide had greater skeletal benefit than those receiving risedronate. SN - 1433-2965 UR - https://www.unboundmedicine.com/medline/citation/22159672/The_effect_of_teriparatide_compared_with_risedronate_on_reduction_of_back_pain_in_postmenopausal_women_with_osteoporotic_vertebral_fractures_ L2 - https://doi.org/10.1007/s00198-011-1856-y DB - PRIME DP - Unbound Medicine ER -